1.36 | +0.0100 | +0.74% | Vol 38.93K | 1Y Perf -41.81% |
Oct 4th, 2023 16:00 DELAYED |
BID | 1.35 | ASK | 1.44 | ||
Open | 1.34 | Previous Close | 1.35 | ||
Pre-Market | - | After-Market | 1.36 | ||
- - | - -% |
Target Price | 12.00 | Analyst Rating | — 0.00 | |
Potential % | 782.35 | Finscreener Ranking | ★★★★★ 58.28 | |
Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★ 46.03 | |
Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★ 44.77 | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 20.69 | Earnings Rating | Buy | |
Market Cap | 67.54M | Earnings Date | 13th Oct 2023 | |
Alpha | -0.01 | Standard Deviation | 0.20 | |
Beta | 0.96 |
Today's Price Range 1.341.39 | 52W Range 1.002.74 | 5 Year PE Ratio Range -100.90121.30 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -2.16% | ||
1 Month | -12.82% | ||
3 Months | -25.68% | ||
6 Months | -44.03% | ||
1 Year | -41.81% | ||
3 Years | -38.46% | ||
5 Years | -64.95% | ||
10 Years | -46.03% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -3.09 | |||
ROE last 12 Months | -52.06 | |||
ROA (5Y Avg) | -2.24 | |||
ROA last 12 Months | -29.91 | |||
ROC (5Y Avg) | -6.57 | |||
ROC last 12 Months | -34.75 | |||
Return on invested Capital Q | -15.24 | |||
Return on invested Capital Y | -10.71 | |||
Assets Turnover | 1.10 | |||
Receivables Turnover | 9.50 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-2.50 | ||||
1.52 | ||||
0.71 | ||||
397.10 | ||||
-3.10 | ||||
-0.40 | ||||
1.82 | ||||
0.92 | ||||
75.57M | ||||
Forward PE | -46.66 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.00 | ||||
1.80 | ||||
0.26 | ||||
0.43 | ||||
- | ||||
Leverage Ratio | 1.70 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
34.70 | ||||
-24.10 | ||||
-21.10 | ||||
-8.20 | ||||
-27.31 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
98.83M | ||||
2.03 | ||||
11.31 | ||||
0.45 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | - | -0.31 | - |
Q02 2023 | - | -0.23 | - |
Q01 2023 | - | -0.18 | - |
Q03 2022 | - | -0.09 | - |
Q02 2022 | - | 0.03 | - |
Q01 2022 | - | -0.04 | - |
Q03 2021 | - | 0.04 | - |
Q02 2021 | - | 0.09 | - |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
1/2018 QR | -0.01 | 0.00 | - |
4/2018 QR | 0.00 | - | - |
7/2018 FY | -0.02 | - | - |
7/2018 FY | -0.03 | 0.00 | - |
Next Report Date | 13th Oct 2023 |
Estimated EPS Next Report | - |
Estimates Count | - |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 38.93K |
Shares Outstanding | 49.66K |
Shares Float | 35.56M |
Trades Count | 229 |
Dollar Volume | 52.85K |
Avg. Volume | 202.85K |
Avg. Weekly Volume | 110.01K |
Avg. Monthly Volume | 166.85K |
Avg. Quarterly Volume | 331.69K |
Enzo Biochem Inc. ($0.01 Par Value) (NYSE: ENZ) stock closed at 1.36 per share at the end of the most recent trading day (a 0.74% change compared to the prior day closing price) with a volume of 38.93K shares and market capitalization of 67.54M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 448 people. Enzo Biochem Inc. ($0.01 Par Value) CEO is Elazar Rabbani.
The one-year performance of Enzo Biochem Inc. ($0.01 Par Value) stock is -41.81%, while year-to-date (YTD) performance is -4.9%. ENZ stock has a five-year performance of -64.95%. Its 52-week range is between 1 and 2.74, which gives ENZ stock a 52-week price range ratio of 20.69%
Enzo Biochem Inc. ($0.01 Par Value) currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 1.52, a price-to-sale (PS) ratio of 0.71, a price to cashflow ratio of 397.10, a PEG ratio of -, a ROA of -29.91%, a ROC of -34.75% and a ROE of -52.06%. The company’s profit margin is -27.31%, its EBITDA margin is -21.10%, and its revenue ttm is $98.83 Million , which makes it $2.03 revenue per share.
Of the last four earnings reports from Enzo Biochem Inc. ($0.01 Par Value), there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Enzo Biochem Inc. ($0.01 Par Value)’s next earnings report date is 13th Oct 2023.
The consensus rating of Wall Street analysts for Enzo Biochem Inc. ($0.01 Par Value) is — (0), with a target price of $12, which is +782.35% compared to the current price. The earnings rating for Enzo Biochem Inc. ($0.01 Par Value) stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enzo Biochem Inc. ($0.01 Par Value) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enzo Biochem Inc. ($0.01 Par Value) has a Sell technical analysis rating based on Technical Indicators (ADX : 13.41, ATR14 : 0.06, CCI20 : -65.88, Chaikin Money Flow : -0.44, MACD : -0.04, Money Flow Index : 54.61, ROC : 3.85, RSI : 38.53, STOCH (14,3) : 25.00, STOCH RSI : 0.00, UO : 31.39, Williams %R : -75.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enzo Biochem Inc. ($0.01 Par Value) in the last 12-months were: Hamid Erfanian (Buy at a value of $197 000), James G. Wolf (Buy at a value of $144 740)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | - | - | Strong Buy |
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
CEO: Elazar Rabbani
Telephone: +1 212 583-0100
Address: 527 Madison Avenue, New York 10022, NY, US
Number of employees: 448
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.